164 related articles for article (PubMed ID: 35392503)
1.
Mohás A; Krencz I; Váradi Z; Arató G; Felkai L; Kiss DJ; Moldvai D; Sebestyén A; Csóka M
Pathol Oncol Res; 2022; 28():1610231. PubMed ID: 35392503
[TBL] [Abstract][Full Text] [Related]
2. Characterization of mTOR Activity and Metabolic Profile in Pediatric Rhabdomyosarcoma.
Felkai L; Krencz I; Kiss DJ; Nagy N; Petővári G; Dankó T; Micsík T; Khoor A; Tornóczky T; Sápi Z; Sebestyén A; Csóka M
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32709151
[TBL] [Abstract][Full Text] [Related]
3. Targeted inhibition of mTORC2 prevents osteosarcoma cell migration and promotes apoptosis.
Wang X; Lai P; Zhang Z; Huang M; Wang L; Yin M; Jin D; Zhou R; Bai X
Oncol Rep; 2014 Jul; 32(1):382-8. PubMed ID: 24840134
[TBL] [Abstract][Full Text] [Related]
4. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.
Martin EC; Rhodes LV; Elliott S; Krebs AE; Nephew KP; Flemington EK; Collins-Burow BM; Burow ME
Mol Cancer; 2014 Oct; 13():229. PubMed ID: 25283550
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
6. Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma.
Krencz I; Sebestyén A; Fábián K; Márk Á; Moldvay J; Khoor A; Kopper L; Pápay J
Hum Pathol; 2017 Apr; 62():66-73. PubMed ID: 28025080
[TBL] [Abstract][Full Text] [Related]
7. Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target.
Hütt-Cabezas M; Karajannis MA; Zagzag D; Shah S; Horkayne-Szakaly I; Rushing EJ; Cameron JD; Jain D; Eberhart CG; Raabe EH; Rodriguez FJ
Neuro Oncol; 2013 Dec; 15(12):1604-14. PubMed ID: 24203892
[TBL] [Abstract][Full Text] [Related]
8. Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction.
Ito M; Yurube T; Kakutani K; Maeno K; Takada T; Terashima Y; Kakiuchi Y; Takeoka Y; Miyazaki S; Kuroda R; Nishida K
Osteoarthritis Cartilage; 2017 Dec; 25(12):2134-2146. PubMed ID: 28888905
[TBL] [Abstract][Full Text] [Related]
9. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
10. In situ analysis of mTORC1/2 and cellular metabolism-related proteins in human Lymphangioleiomyomatosis.
Krencz I; Sebestyen A; Papay J; Jeney A; Hujber Z; Burger CD; Keller CA; Khoor A
Hum Pathol; 2018 Sep; 79():199-207. PubMed ID: 29885404
[TBL] [Abstract][Full Text] [Related]
11. Hyperglycemia-induced Bcl-2/Bax-mediated apoptosis of Schwann cells via mTORC1/S6K1 inhibition in diabetic peripheral neuropathy.
Zhu L; Hao J; Cheng M; Zhang C; Huo C; Liu Y; Du W; Zhang X
Exp Cell Res; 2018 Jun; 367(2):186-195. PubMed ID: 29621478
[TBL] [Abstract][Full Text] [Related]
12. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
13. Role of crosstalk between STAT3 and mTOR signaling in driving sensitivity to chemotherapy in osteosarcoma cell lines.
Wang YT; Tang F; Hu X; Zheng CX; Gong TJ; Zhou Y; Luo Y; Min L
IUBMB Life; 2020 Oct; 72(10):2146-2153. PubMed ID: 33448097
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways.
Xu C; Liu C; Liu L; Zhang R; Zhang H; Chen S; Luo Y; Chen L; Huang S
Neuropharmacology; 2015 Oct; 97():35-45. PubMed ID: 26002629
[TBL] [Abstract][Full Text] [Related]
17. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling.
Julien LA; Carriere A; Moreau J; Roux PP
Mol Cell Biol; 2010 Feb; 30(4):908-21. PubMed ID: 19995915
[TBL] [Abstract][Full Text] [Related]
18. MITF-MIR211 axis is a novel autophagy amplifier system during cellular stress.
Ozturk DG; Kocak M; Akcay A; Kinoglu K; Kara E; Buyuk Y; Kazan H; Gozuacik D
Autophagy; 2019 Mar; 15(3):375-390. PubMed ID: 30290719
[TBL] [Abstract][Full Text] [Related]
19. Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells.
Hoshii T; Kasada A; Hatakeyama T; Ohtani M; Tadokoro Y; Naka K; Ikenoue T; Ikawa T; Kawamoto H; Fehling HJ; Araki K; Yamamura K; Matsuda S; Hirao A
Proc Natl Acad Sci U S A; 2014 Mar; 111(10):3805-10. PubMed ID: 24567410
[TBL] [Abstract][Full Text] [Related]
20. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
